FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282970206> ?p ?o ?g. }

• W4282970206 endingPage "1086" @default.
• W4282970206 startingPage "1086" @default.
• W4282970206 abstract "Abstract Introduction: The Ewing family of sarcomas is the fourth most common highly malignant childhood cancer. Current standard therapy is relatively ineffective for relapsed and metastatic Ewing sarcoma predominantly due to development of resistance to chemotherapeutics. Nanoparticle-formulated drugs are reported to increase uptake into tumor tissue, while reducing drug access to normal tissues, because of reduced permeability of normal vasculature. This potentially leads to lower dose exposure in normal tissues and reduced toxicity. The purpose of this study was to evaluate the antitumor activity of the PEGylated poly(ADP) ribose polymerase 1/2 (PARP1/2) inhibitor talazoparib combined with the DNA alkylating agent temozolomide (TMZ) in Ewing sarcoma xenograft models and other pediatric cancers. Method:. We evaluated the preclinical efficacy of PEGylated talazoparib (PEG~TLZ), alone or in combination with TMZ, in Ewing sarcoma and glioblastoma patient derived xenograft (PDX) models. Additional solid tumor models, such as rhabdomyosarcoma, Wilms tumor, malignant rhabdoid tumor, osteosarcoma, and synovial sarcoma were evaluated using a novel single mouse testing approach. PEG~TLZ was administered as a single administration intraperitoneally to mice bearing subcutaneous tumors at a single dose of 5 - 20 µmol/kg alone, or at 10 µmol/kg on day 1 combined with TMZ administered orally at 40 mg/kg starting on day 3 or 4 for 5 consecutive days. Results: Mice bearing Ewing sarcoma and MGMT-deficient glioblastoma xenografts tolerated PEG~TLZ+TMZ with minimal toxicity and achieved maintained complete response (MCR). The time-separated drug administration schedule of the single dose of PEG~TLZ followed by the 5-day TMZ treatment demonstrated objective responses in Ewing sarcoma, rhabdoid tumor, rhabdomyosarcoma, and glioblastoma PDX models. Conclusion: We evaluated the range of PEG~TLZ+TMZ activity among pediatric solid tumor panels using conventional and single-mouse testing approaches, and demonstrated that PEG~TLZ combined with delayed TMZ administration enhances the therapeutic window of the treatment compared to free TLZ. From the clinical standpoint, the single intravenous administration of PEG~TLZ could be advantageous for treating infants and young children. Citation Format: Vanessa Del Pozo, Andrew J. Robles, Shaun Fontaine, Qianqian Liu, Joel E. Michalek, Peter J. Houghton, Raushan Kurmasheva. PEGylated talazoparib enhances therapeutic window of its combination with temozolomide in Ewing sarcoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1086." @default.
• W4282970206 created "2022-06-17" @default.
• W4282970206 creator A5004648382 @default.
• W4282970206 creator A5011706450 @default.
• W4282970206 creator A5019498881 @default.
• W4282970206 creator A5028433300 @default.
• W4282970206 creator A5044445972 @default.
• W4282970206 creator A5049292941 @default.
• W4282970206 creator A5063003513 @default.
• W4282970206 date "2022-06-15" @default.
• W4282970206 modified "2023-10-18" @default.
• W4282970206 title "Abstract 1086: PEGylated talazoparib enhances therapeutic window of its combination with temozolomide in Ewing sarcoma" @default.
• W4282970206 doi "https://doi.org/10.1158/1538-7445.am2022-1086" @default.
• W4282970206 hasPublicationYear "2022" @default.
• W4282970206 type Work @default.
• W4282970206 citedByCount "0" @default.
• W4282970206 crossrefType "journal-article" @default.
• W4282970206 hasAuthorship W4282970206A5004648382 @default.
• W4282970206 hasAuthorship W4282970206A5011706450 @default.
• W4282970206 hasAuthorship W4282970206A5019498881 @default.
• W4282970206 hasAuthorship W4282970206A5028433300 @default.
• W4282970206 hasAuthorship W4282970206A5044445972 @default.
• W4282970206 hasAuthorship W4282970206A5049292941 @default.
• W4282970206 hasAuthorship W4282970206A5063003513 @default.
• W4282970206 hasConcept C121608353 @default.
• W4282970206 hasConcept C126322002 @default.
• W4282970206 hasConcept C142724271 @default.
• W4282970206 hasConcept C2776694085 @default.
• W4282970206 hasConcept C2777389519 @default.
• W4282970206 hasConcept C2777586341 @default.
• W4282970206 hasConcept C2778256501 @default.
• W4282970206 hasConcept C2780844630 @default.
• W4282970206 hasConcept C2780964509 @default.
• W4282970206 hasConcept C29730261 @default.
• W4282970206 hasConcept C2993561819 @default.
• W4282970206 hasConcept C502942594 @default.
• W4282970206 hasConcept C71924100 @default.
• W4282970206 hasConcept C98274493 @default.
• W4282970206 hasConceptScore W4282970206C121608353 @default.
• W4282970206 hasConceptScore W4282970206C126322002 @default.
• W4282970206 hasConceptScore W4282970206C142724271 @default.
• W4282970206 hasConceptScore W4282970206C2776694085 @default.
• W4282970206 hasConceptScore W4282970206C2777389519 @default.
• W4282970206 hasConceptScore W4282970206C2777586341 @default.
• W4282970206 hasConceptScore W4282970206C2778256501 @default.
• W4282970206 hasConceptScore W4282970206C2780844630 @default.
• W4282970206 hasConceptScore W4282970206C2780964509 @default.
• W4282970206 hasConceptScore W4282970206C29730261 @default.
• W4282970206 hasConceptScore W4282970206C2993561819 @default.
• W4282970206 hasConceptScore W4282970206C502942594 @default.
• W4282970206 hasConceptScore W4282970206C71924100 @default.
• W4282970206 hasConceptScore W4282970206C98274493 @default.
• W4282970206 hasIssue "12_Supplement" @default.
• W4282970206 hasLocation W42829702061 @default.
• W4282970206 hasOpenAccess W4282970206 @default.
• W4282970206 hasPrimaryLocation W42829702061 @default.
• W4282970206 hasRelatedWork W170696954 @default.
• W4282970206 hasRelatedWork W1918281504 @default.
• W4282970206 hasRelatedWork W2153391601 @default.
• W4282970206 hasRelatedWork W2489108290 @default.
• W4282970206 hasRelatedWork W2519029083 @default.
• W4282970206 hasRelatedWork W3049600046 @default.
• W4282970206 hasRelatedWork W3083761066 @default.
• W4282970206 hasRelatedWork W3169763413 @default.
• W4282970206 hasRelatedWork W4224049892 @default.
• W4282970206 hasRelatedWork W4282970206 @default.
• W4282970206 hasVolume "82" @default.
• W4282970206 isParatext "false" @default.
• W4282970206 isRetracted "false" @default.
• W4282970206 workType "article" @default.